IL261428B2

Eribulin-based antibody-drug conjugates and methods of use

Abstract

This record has no abstract on file.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

Every citation, both ways

Citations
DocumentRelationOfficeCategoryCited duringRelevant claims
WO2005080431A2CitesWorld Intellectual Property Organization (WIPO)YSearch report1-50
WO2013130093A1CitesWorld Intellectual Property Organization (WIPO)YSearch report1-50
WO2014089335A2CitesWorld Intellectual Property Organization (WIPO)YSearch report1-50
NARAYAN, SRIDHAR, ET AL., NOVEL SECOND GENERATION ANALOGS OF ERIBULIN. PART II: ORALLY AVAILABLE AND ACTIVE AGAINST RESISTANT TUMORS IN VIVO., 20 January 2011 (2011-01-20)Non-patentSearch report
TOWLE, MURRAY J., ET AL., ERIBULIN INDUCES IRREVERSIBLE MITOTIC BLOCKADE: IMPLICATIONS OF CELL-BASED PHARMACODYNAMICS FOR IN VIVO EFFICACY UNDER INTERMITTENT DOSING CONDITIONS., 2 December 2010 (2010-12-02)Non-patentSearch report
ZHANG, NINGYAN, ET AL., TRASTUZUMAB-DOXORUBICIN CONJUGATE PROVIDES ENHANCED ANTI-CANCER POTENCY AND REDUCED CARDIOTOXICITY., 28 February 2013 (2013-02-28)Non-patentSearch report